Literature DB >> 19867668

THE RESULTS OF THE SERUM TREATMENT IN THIRTEEN HUNDRED CASES OF EPIDEMIC MENINGITIS.

S Flexner1.   

Abstract

The data brought together in this report have been gathered from a wide territory and for a period extending over several years. The antimeningitis serum was first employed in 1906 and the latest figures relating to its use included in this report were furnished in 1912. There is no longer doubt that the serum has come to be applied under conditions fairly representing all known manifestations of epidemic meningitis. Hence the test of the serum treatment may be regarded as having been a rigorous one. The initial difficulties surrounding the administration by direct subdural injection have been largely overcome and doubtless will be still further mastered. Already the serum is being successfully applied in private as well as in hospital practice. This gain will probably be reflected in a still further diminution of the mortality since early injection plays such a large part in determining the results achieved. The 1,300 cases studied in this report are a part only of a far greater number of cases actually treated with the serum supplied by the Rockefeller Institute. It was not found possible to secure histories of all the cases treated; but there is no reason to suppose that the results of the analysis would have been essentially different if reports of a still larger number of cases had been returned. The decision arrived at is not based upon statistical computations alone, but upon objective data as well that are not readily misinterpreted. The conclusion that follows was first stated in 1909 as the result of an analysis of 400 serum-treated cases. It is supported by the study of the larger series of cases just presented. "In view of the various considerations presented, the conclusion may be drawn that the antimeningitis serum, when used by the subdural method of injection, in suitable doses and at proper intervals, is capable of reducing the period of illness; of preventing, in large measure, the chronic lesions and types of the infection; of bringing about complete restoration of health, in all but a very small number of the recovered, thus lessening the serious, deforming, and permanent consequences of meningitis; and of greatly diminishing the fatalities due to the disease."

Entities:  

Year:  1913        PMID: 19867668      PMCID: PMC2125091          DOI: 10.1084/jem.17.5.553

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  33 in total

1.  Correlation between serum bactericidal activity against Neisseria meningitidis serogroups A, C, W-135 and Y measured using human versus rabbit serum as the complement source.

Authors:  C J Gill; S Ram; J A Welsch; L Detora; A Anemona
Journal:  Vaccine       Date:  2011-11-07       Impact factor: 3.641

Review 2.  Effectiveness of antibiotics given before admission in reducing mortality from meningococcal disease: systematic review.

Authors:  Susan J M Hahné; André Charlett; Bernadette Purcell; Susanne Samuelsson; Ivonne Camaroni; Ingrid Ehrhard; Sigrid Heuberger; Maria Santamaria; James M Stuart
Journal:  BMJ       Date:  2006-06-03

3.  Antibody prophylaxis and therapy against Nipah virus infection in hamsters.

Authors:  V Guillaume; H Contamin; P Loth; I Grosjean; M C Georges Courbot; V Deubel; R Buckland; T F Wild
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

4.  Hospital-based surveillance of meningococcal meningitis in Salvador, Brazil.

Authors:  Soraia M Cordeiro; Alan B Neves; Cássio T Ribeiro; Maya L Petersen; Edilane L Gouveia; Guilherme S Ribeiro; Tatiana S Lôbo; Joice N Reis; Kátia M Salgado; Mitermayer G Reis; Albert I Ko
Journal:  Trans R Soc Trop Med Hyg       Date:  2007-08-06       Impact factor: 2.184

Review 5.  Prospects for vaccine prevention of meningococcal infection.

Authors:  Lee H Harrison
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

Review 6.  Evolutionary and genomic insights into meningococcal biology.

Authors:  Holly B Bratcher; Julia S Bennett; Martin C J Maiden
Journal:  Future Microbiol       Date:  2012-07       Impact factor: 3.165

7.  SARS-CoV-2 viral load and antibody responses: the case for convalescent plasma therapy.

Authors:  Arturo Casadevall; Michael J Joyner; Liise-Anne Pirofski
Journal:  J Clin Invest       Date:  2020-10-01       Impact factor: 14.808

Review 8.  Update on meningococcal disease with emphasis on pathogenesis and clinical management.

Authors:  M van Deuren; P Brandtzaeg; J W van der Meer
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

9.  Potential role of IgM-enriched immunoglobulin as adjuvant treatment for invasive meningococcal disease.

Authors:  Carlo Tascini; Fiorentino Fraganza; Francesca Salani; Emanuela Sozio; Marco Rossi; Francesco Sbrana; Novella Carannante; Maria Daniela Chiesa; Andrea Ripoli; Giacomo Bertolino; Massimo Di Pietro; Alessandro Bartoloni; Francesco Menichetti
Journal:  Intensive Care Med       Date:  2017-11-09       Impact factor: 17.440

10.  THE FUNCTIONAL EFFECT OF EXPERIMENTAL INTRASPINAL INJECTIONS OF SERA WITH AND WITHOUT PRESERVATIVES.

Authors:  J Auer
Journal:  J Exp Med       Date:  1915-01-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.